更新于：2024-11-01

TF antigen

更新于：2024-11-01

基本信息

别名-

简介-

关联

项与 TF antigen 相关的药物

hJAA-F11

靶点

TF antigen

作用机制

TF antigen inhibitors

在研机构

For-Robin, Inc.

原研机构

For-Robin, Inc.

在研适应症

肺癌 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

CD176-CAR-Ts(Glycotope GmbH)

CD176靶向CAR-T(Glycotope GmbH)

靶点

TF antigen

作用机制

TF antigen modulators

在研机构

Hannover Medical School [+1]

原研机构

Hannover Medical School [+1]

在研适应症

白血病 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 TF antigen 相关的临床结果

登录后查看更多信息

100 项与 TF antigen 相关的转化医学

登录后查看更多信息

0 项与 TF antigen 相关的专利（医药）

登录后查看更多信息

674

项与 TF antigen 相关的文献（医药）

2024-10-10·Journal of Medicinal Chemistry

Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development

Article

作者: Liu, Zhongqiu ; Li, Jinmei ; Liao, Guochao ; Ming, Wenbo ; Luo, Xiang ; Liao, Pan ; Yang, Deying ; Li, Xiaohui ; Liu, Zichun ; Li, Tongtong

The Thomsen-Friedenreich (TF) antigen has proven to be a promising target for developing novel therapeutic cancer vaccines. Here, a new strategy that TF antigen covalently coupled with KRN7000 and vizantin was developed. The resulting three-component vaccine KRN7000-TF-vizantin simultaneously triggers invariant natural killer T (iNKT) cells and macrophage-inducible C-type lectin (Mincle) signaling pathways, eliciting much stronger TF-specific immune responses than glycoprotein vaccine TF-KLH/alum and the corresponding two-component conjugate vaccines TF-KRN7000 and TF-vizantin. The analysis of IgG isotypes and the secretion of cytokines revealed that KRN7000-TF-vizantin induced Th1/Th2 mixed immune responses, where Th1 was dominant. In vivo experiments demonstrated that KRN7000-TF-vizantin increased the survival rate and survival time of tumor-challenged mice, and surviving mice rejected further tumor attacks without any additional treatment. This work demonstrates that covalently coupled KRN7000 and vizantin could serve as a promising TF-based vaccine carrier for antitumor immune therapy, and KRN7000-TF-vizantin features great potential to be a vaccine candidate.

2024-03-01·International Journal of Biological Macromolecules

Cancer snap-shots: Biochemistry and glycopathology of O-glycans: A review

Review

作者: Sanji, Ashwini S ; J, Manasa ; Gurav, Maruti J ; Chachadi, Vishwanath B ; Batra, Surinder K

Cancer pathogenesis is strongly linked to the qualitative and quantitative alteration of the cell surface glycans, that are glycosidically linked to proteins and lipids. Glycans that are covalently linked to the polypeptide backbone of a protein through nitrogen or oxygen, are known as N-glycans or O-glycans, respectively. Although the role of glycans in the expression, physiology, and communication of cells is well documented, the function of these glycans in tumor biology is not fully elucidated. In this context, current review summarizes biosynthesis, modifications and pathological implications of O-glycans The review also highlights illustrative examples of cancer types modulated by aberrant O-glycosylation. Related O-glycans like Thomsen-nouveau (Tn), Thomsen-Friedenreich (TF), Lewis^a/x, Lewis^b/y, sialyl Lewis^a/x and some other O-glycans are discussed in detail. Since, the overexpression of O-glycans are attributed to the aggressiveness and metastatic behavior of cancer cells, the current review attempts to understand the relation between metastasis and O-glycans.

2024-02-01·Bioorganic & Medicinal Chemistry

Chemoenzymatic synthesis and immunological evaluation of sialyl-Thomsen-Friedenreich (sTF) antigen conjugate to CRM197

Article

作者: Zhang, Wei ; Weng, Weizhao ; Zong, Chengli ; Teng, Changcai ; Ding, Ning ; Guo, Jia ; Guo, Qiuyu ; Ren, Sumei

sTF (sialyl-Thomsen-Friedenreich) is a type of tumor-associated carbohydrate antigens (TACAs) and is highly expressed in various human malignancies. To validate if sTF could be a valuable molecular target for future cancer vaccine development, in this work the sTF antigen was prepared by adopting a strategy combining chemical and enzymatic methods, and then was covalently conjugated to a carrier protein, CRM197. The preliminary immunological evaluation, performed on BALB/c mice, revealed that the sTF-CRM197 conjugate elicited high titers of specific IgG antibodies. FACS experiments showed that the antisera induced by sTF-CRM197 conjugate could specifically recognize and bind to sTF-positive cancer cells T-47D. Furthermore, the conjugate mediated effective and specific antibody-mediated complement-dependent cytotoxicity (CDC).